Vir Biotechnology, Inc. (VIR) Investor Relations Documents

Vir Biotechnology, Inc. (VIR) investor relations documents from the company's IR site: 4 presentations, 15 press releases; latest deck 2026-05-29. Read in-app with summaries. First-party data.

Presentationfor Vir Biotechnology EASL Oral Presentation - 05/29/2026 (opens in new window) — The Phase 2 SOLSTICE trial reports that 88% of chronic HDV patients achieved undetectable viral RNA at Week 96 using the tobevibart and elebsiran combination.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releaseVir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-08-05Press releasePress Release
2026-07-24Press releaseVir Biotechnology Announces Chief Financial Officer Transition
2026-07-22Press releaseVir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
2026-06-10Press releaseVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
2026-05-29PresentationPresentationfor Vir Biotechnology EASL Oral Presentation - 05/29/2026 (opens in new window)
2026-05-27Press releaseVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the Europe
2026-05-18Press releaseVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the Europe
2026-05-12Press releaseVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
2026-05-06Press releaseVir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
2026-05-05Press releaseVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
2026-04-13Press releaseVir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Du
2026-03-02Press releaseVir Biotechnology to Participate in Upcoming Investor Conferences
2026-02-25PresentationPresentationfor Vir Biotechnology ASCO GU 2026 Presentation - 02/26/2026 (opens in new window)
2026-02-24Press releaseVir Biotechnology Announces Proposed Public Offering of Common Stock
2026-02-24Press releaseVir Biotechnology Announces Pricing of Public Offering of Common Stock
2026-02-23Press releaseVir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
2026-01-15PresentationPresentationfor Vir Biotechnology Corporate Overview Presentation - 01/14/2026 (opens in new window)
2026-01-14PresentationPresentationfor 44th Annual J.P. Morgan Healthcare Conference - 01/14/2026 (opens in new window)

VIR overview · VIR earnings · VIR financials · VIR KPIs · VIR ownership · VIR peers · VIR filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.